首页> 外文期刊>Biomedical Chromatography: An International Journal Devoted to Research in Chromatographic Methodologies and Their Applications in the Biosciences >High‐throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry
【24h】

High‐throughput screening assay for the quantification of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 in HepG2 cells using RapidFire mass spectrometry

机译:用于定量CER D18:1/16:0,D18:1/24:0,D18:1/24:1,D18:1/18:0,D18:1/14:0,D18:1/14:0, D18:1/20:0,D18:1/22:0,使用RapidFire质谱法在HepG2细胞中

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Ceramides are known to be involved in various biological processes with their physiological levels elevated in various disease conditions such as diabetes, Alzheimer's, atherosclerosis. To facilitate the rapid screening of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 inhibition in HepG2 cells, a RapidFire coupled to tandem mass spectrometry (RF–MS/MS) method has been developed. The RF platform provides an automated solid‐phase extraction system that gave a throughput of 12.6?s per sample to an MS/MS system using electrospray ionization under the positive ion mode. Chromatographic separation of Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, and d18:1/22:0 was achieved using a ternary gradient on C 8 type E cartridge. The MS/MS ion transitions monitored were 538.2?→?264.2, 650.7?→?264.2, 648.6?→?264.2, 566.4?→?264.2, 510.4?→?264.2, 594.4?→?264.2, 622.5?→?264.2, and 552.3?→?250.2 for Cer d18:1/16:0, d18:1/24:0, d18:1/24:1, d18:1/18:0, d18:1/14:0, d18:1/20:0, d18:1/22:0, and the internal standard (Cer d17:1/18:0), respectively. The RF–MS/MS methodology showed an excellent performance with an average Z′ value of 0.5–0.7. This is the first report of an RF–MS/MS assay for screening of ceramides which is amenable for high‐throughput screening.
机译:众所周知,摘要宫殿涉及各种生物过程,其生理水平在各种疾病病症如糖尿病,阿尔茨海默氏症,动脉粥样硬化。为了便于CER D18:1/16:0,D18:1/24:0,D18:1/18:0,D18:1/14:0,D18:1/18:0,D18:1的快速筛查/ 20:0和D18:1/22:0抑制在HepG2细胞中,已经开发了耦合到串联质谱(RF-MS / MS)方法的RapidFire。 RF平台提供自动化的固相提取系统,其在正离子模式下使用电喷雾电离将每种样本的12.6°S的吞吐量为12.6°S到MS / MS系统。 CER D18:1/16:0,D18:1/24:0,D18:1/18:0,D18:1/18:0,D18:1/18:0,D18:1/25:在C 8型盒上使用三元梯度实现0和D18:1/22:0。监测的MS / MS离子过渡为538.2?→264.2,650.7?→264.2,60.6?→264.2,566.4?→264.2,510.4?→264.2,594.4?→264.2,622.5?→264.2, 552.3?→250.2对于CER D18:1/16:0,D18:1/24:0,D18:1/24:1,D18:1/18:0,D18:1/14:0,D18: 1/20:0,D18:1/22:0,以及内部标准(CER D17:1/18:0)。 RF-MS / MS方法显示出优异的性能,平均Z'值为0.5-0.7。这是RF-MS / MS测定的第一个报告,用于筛选可用于高通量筛选的酰胺酰胺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号